Immunotherapy After Kidney Cancer Surgery Improves Overall Survival

Recently published in the New England Journal of Medicine, findings from the pivotal phase 3 trial, KEYNOTE-564, underscore a crucial development in adjuvant therapy for patients diagnosed with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence.

Led by Dr. Toni Choueiri, the study demonstrates the remarkable efficacy of pembrolizumab, an immunotherapy drug, in extending overall survival rates following surgical intervention. Patients administered pembrolizumab exhibited a notable 38% reduction in the risk of mortality compared to those receiving a placebo. This pivotal trial represents a significant milestone, marking the first instance in fifty years that an adjuvant therapy has showcased such a substantial survival benefit in the treatment of kidney cancer. Pembrolizumab’s mechanism of action, targeting cancer cells’ immune evasion pathways, offers promising prospects for individuals grappling with this complex malignancy.

For access the full general article here

For comprehensive insights into this study see the New England Journal of Medicine here

At Kidney Cancer UK, our commitment to advancing knowledge and support for patients, caregivers, and healthcare professionals remains unwavering.